Biologics and immunomodulators (IMM) are generally considered the most effective therapies for the treatment of ulcerative colitis and Crohn's disease. However, despite the efficacy of these therapies, many patients either have a primary lack of response or a secondary loss of response to these medications. Therapeutic drug monitoring (TDM) is a systematic approach to managing such patients. In this review, we summarize the latest data on TDM, including reactive and proactive TDM, in patients with inflammatory bowel disease on biologics and/or IMM.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185221 | PMC |
| http://dx.doi.org/10.3748/wjg.v28.i21.2282 | DOI Listing |
Publication Analysis
Top Keywords
therapeutic drug
8
drug monitoring
8
inflammatory bowel
8
bowel disease
8
disease biologics
8
updates therapeutic
4
monitoring inflammatory
4
biologics immunomodulators
4
immunomodulators imm
4
imm generally
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!